<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05610085</url>
  </required_header>
  <id_info>
    <org_study_id>FD-R-6335</org_study_id>
    <nct_id>NCT05610085</nct_id>
  </id_info>
  <brief_title>A Dose Escalation Study of Levetiracetam in the Treatment of Neonatal Seizures</brief_title>
  <acronym>NEOLEV3</acronym>
  <official_title>A Phase IIb Dose Escalation Study of Levetiracetam for the Treatment of Neonatal Seizures</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, San Diego</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Minnesota</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Rady Children's Hospital, San Diego</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Auckland City Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Sharp Mary Birch Hospital for Women &amp; Newborns</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Auckland, New Zealand</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Middlemore Hospital, New Zealand</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of California, San Diego</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main purpose of this study is to determine the maximum safe tolerated dose of LEV in the&#xD;
      treatment of neonatal seizures. Our hypothesis is that optimal dosing of Levetiracetam (LEV)&#xD;
      to treat neonatal seizures is significantly greater than 60mg/kg. This study will be an open&#xD;
      label dose-escalation, preliminary safety and efficacy study. There will be a randomized&#xD;
      control treatment component. Infants recognized as having neonatal seizures or as being at&#xD;
      risk of developing seizures will be recruited and started on continuous video EEG monitoring&#xD;
      (CEEG). Eligibility will be confirmed and consent will be obtained. In the first 2 phases of&#xD;
      the study, neurologists will identify neonates with mild-moderate seizure burden (less than 8&#xD;
      minutes cumulative seizure activity per hour), appropriate for study with LEV, and exclude&#xD;
      patients with higher seizure burden where treatment with PHB is more appropriate. Phase 3 of&#xD;
      the dose escalation will only proceed if additional efficacy of LEV has been demonstrated in&#xD;
      phases 1 and 2. In Phase 3 we will recruit neonates with seizures of greater severity up to&#xD;
      30 minute seizure burden/hour. This will make the final results of study more generalizable.&#xD;
&#xD;
      If seizures are confirmed, enrolled subjects will receive 60mg/kg of LEV. Subjects whose&#xD;
      seizures persist or recur 15 minutes after the first infusion is complete, subjects will then&#xD;
      be randomized in the dose escalation study. Patients in the dose escalation study will be&#xD;
      randomly assigned to receive either higher dose LEV or treatment with the control drug PHB in&#xD;
      a 3:1 allocation ratio, stratified by site.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Aims/Hypotheses:&#xD;
&#xD;
      Primary Aim: To determine the recommended maximal safe dose of LEV in the setting of neonatal&#xD;
      seizures of mild to moderate severity.&#xD;
&#xD;
      If 60mg/kg LEV does not control seizures, subjects will be randomised to receive either&#xD;
      additional LEV or PHB. LEV dose will be escalated in 30mg/kg increments to a maximal dose of&#xD;
      150mg/kg total loading dose. We will use a continual reassessment method to determine the&#xD;
      maximal safe and tolerated dose.&#xD;
&#xD;
      Secondary/exploratory aims:&#xD;
&#xD;
        -  To study the pharmacokinetics of high dose LEV in neonates with seizures of mild to&#xD;
           moderate severity.&#xD;
&#xD;
        -  To estimate the additional efficacy of higher doses of LEV in neonates with seizures of&#xD;
           mild to moderate severity.&#xD;
&#xD;
        -  To improve technologies for the prompt detection of neonatal seizures: We will assess&#xD;
           the latest version of Persyst's neonatal seizure detector.&#xD;
&#xD;
      Research Design&#xD;
&#xD;
      This is a Phase IIb, open label dose-escalation, preliminary safety and efficacy study. An&#xD;
      active drug treatment control arm (PHB group) is included in the study design. This study is&#xD;
      not designed or powered to compare high dose LEV and PHB groups, however, the randomized&#xD;
      control group will help with interpretation of adverse events and seizure cessation efficacy&#xD;
      seen in the high dose escalation group. This is particularly important because of the high&#xD;
      rates of morbidity in neonates with seizures.&#xD;
&#xD;
      24-hour seizure control endpoint: cEEG reviewed by a neurophysiologist will be used for&#xD;
      assessing 24-hour seizure control. Treatment will be considered effective in achieving&#xD;
      24-hour seizure control if there is a seizure burden less than 30 seconds in the 24 hours&#xD;
      following the dose. Change in seizure burden in 2-hour post treatment period will also be&#xD;
      assessed.&#xD;
&#xD;
      Intervention If seizure activity occurs participants will be enrolled and will receive&#xD;
      60mg/kg LEV.&#xD;
&#xD;
      If seizures continue babies will then be randomised to receive either:&#xD;
&#xD;
        -  Additional LEV at a higher dose (30 mg/kg, 60 mg/kg, or 90 mg/kg depending on the stage&#xD;
           of the study), OR&#xD;
&#xD;
        -  PHB at 20-40 mg/kg. Maintenance treatment will continue for 5 days, either IV or orally&#xD;
           if baby is tolerating feeds.&#xD;
&#xD;
      LEV discontinuation or addition of PHB: there are multiple criteria for transition to, or&#xD;
      addition of, PHB treatment if required for seizure control.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 24, 2023</start_date>
  <completion_date type="Anticipated">December 31, 2026</completion_date>
  <primary_completion_date type="Anticipated">July 1, 2026</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>If seizures persist or recur after 60 mg/kg LEV patients will be randomized to receive either dose escalation of levetiracetam or phenobarbital. Randomization will occur in a 3:1 ratio LEv: PHB stratified by site.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The primary endpoint is the maximum safe and tolerated dose of Levetiracetam</measure>
    <time_frame>4 years</time_frame>
    <description>A continual reassessment method will be used to determine the maximal safe and tolerated dose</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Levetiracetam CL</measure>
    <time_frame>4 years</time_frame>
    <description>Population pharmacokinetic parameters for LEV Clearance (CL)will be calculated</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Levetiracetam Vd</measure>
    <time_frame>4 years</time_frame>
    <description>Population pharmacokinetic parameters for LEV Volume of distribution (Vd) will be calculated</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse event rates</measure>
    <time_frame>4 years</time_frame>
    <description>Rates of adverse events seen with high dose LEV treatment will be reported and compared to rates seen in PHB control arm.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Long-term outcome</measure>
    <time_frame>8 years</time_frame>
    <description>Rates of adverse long-term outcome ( Death or Disability at 24 months) will be compared between treatment arms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Seizure burden reduction</measure>
    <time_frame>4 years</time_frame>
    <description>Number of patients with at least 50% seizure burden reduction post treatment will be compared between randomized treatment arms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Seizure freedom rates</measure>
    <time_frame>4 years</time_frame>
    <description>Number of patients who become seizure free for 24 hours post treatment will be compared between the randomized treatment groups in each stage of the study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Estimate of efficacy of higher dose LEV</measure>
    <time_frame>4 years</time_frame>
    <description>Assuming no dose limiting toxicity is demonstrated and the study proceeds to completion, 50 subjects will be treated at 120mg/kg or higher dosing level. This sample size will give satisfactory power for estimating additional efficacy of higher doses. For example, if we document an additional response rate of 15%, this sample size will provide a 95% confidence interval (0.051, 0.248) around that estimate.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">133</enrollment>
  <condition>Neonatal Seizure</condition>
  <condition>Neonatal Encephalopathy</condition>
  <condition>Hypoxic-Ischemic Encephalopathy</condition>
  <condition>Seizure Newborn</condition>
  <arm_group>
    <arm_group_label>Dose escalation with LEV</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Additional LEV at a higher dose (30 mg/kg, 60 mg/kg, or 90 mg/kg depending on the stage of the study).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard of care Phenobarbital</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Treatment with Phenobarbital 20mg/kg IV and if needed a further 20mg/kg totalling 40mg/kg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Levetiracetam Injection</intervention_name>
    <description>Neonates will be treated with intravenous levetiracetam 60mg/kg for first line management of seizures, and if seizures persist will be randomized to receive higher dose Levetiracetam or standard of care phenobarbital</description>
    <arm_group_label>Dose escalation with LEV</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Phenobarbital Sodium Injection</intervention_name>
    <description>Standard of care for neonatal seizures</description>
    <arm_group_label>Standard of care Phenobarbital</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  at risk for seizures or suspected to be having seizures;&#xD;
&#xD;
          -  all seizure aetiologies except correctable metabolic abnormalities such as&#xD;
             hypoglycaemia and hypocalcaemia;&#xD;
&#xD;
          -  Term neonates (corrected gestational age between 35 and 44 weeks, postnatal age less&#xD;
             than 28 days);&#xD;
&#xD;
          -  weight &gt; 2200g.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Cumulative seizure burden of 8 minutes/ hour or more in phases 1 and 2, Cumulative&#xD;
             seizure burden of 30 minutes/hour or more in phase 3;&#xD;
&#xD;
          -  Renal failure defined as anuria in the first 24 hours of life;&#xD;
&#xD;
          -  Subjects in whom death seems imminent;&#xD;
&#xD;
          -  Seizures caused by correctable metabolic abnormality, such as hypocalcaemia,&#xD;
             hypoglycaemia.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>1 Month</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sonya G Wang, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Minnesota</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Cynthia M Sharpe, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Auckland City Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jeff J Gold, M.D. PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, San Diego</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Richard H Haas, MBBChir</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, San Diego</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sonya G Wang, M.D.</last_name>
    <phone>612-301-1454</phone>
    <email>sgwang@umn.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Brittany Faanes, MPH</last_name>
    <phone>612-625-5929</phone>
    <email>grego318@umn.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of California, San Diego</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92093</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jeff Gold, M.D.</last_name>
      <email>jjgold@health.ucsd.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Auckland City Hospital</name>
      <address>
        <city>Auckland</city>
        <zip>1023</zip>
        <country>New Zealand</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cynthia Sharpe, MBChB</last_name>
      <phone>021924015</phone>
      <email>cynthias@adhb.govt.nz</email>
    </contact>
  </location>
  <location_countries>
    <country>New Zealand</country>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2023</verification_date>
  <study_first_submitted>October 27, 2022</study_first_submitted>
  <study_first_submitted_qc>November 6, 2022</study_first_submitted_qc>
  <study_first_posted type="Actual">November 9, 2022</study_first_posted>
  <last_update_submitted>April 27, 2023</last_update_submitted>
  <last_update_submitted_qc>April 27, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">May 1, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of California, San Diego</investigator_affiliation>
    <investigator_full_name>Richard H. Haas</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Seizures</mesh_term>
    <mesh_term>Brain Diseases</mesh_term>
    <mesh_term>Brain Ischemia</mesh_term>
    <mesh_term>Hypoxia-Ischemia, Brain</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Levetiracetam</mesh_term>
    <mesh_term>Phenobarbital</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

